Dutch diagnostics player Qiagen confirms buyout talks following report of Thermo Fisher's interest
Several bidders have laid their eyes on Dutch diagnostics firm Qiagen — and Thermo Fisher is reportedly one of them.
Qiagen, which is listed on the NYSE, notified investors on Friday that “it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company.” It didn’t name any of the potential buyers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.